October 16
DTx proof-of-concept results presented at CHEST 2025 in Chicago: 41.8% reduction in cough frequency and 80% of participants reporting clinically meaningful improvement in quality of life.
Our validated, privacy-preserving, on-device detection quantifies cough frequency and patterns in real-world conditions with high participant adherence, producing data that is clinically interpretable and operationally practical at scale. Hyfe’s cough monitoring technology takes participant privacy extremely seriously and at no point conversations or audio can be listened to, there are no audio recordings stored, just timestamps of coughs processed in real time as the system passively monitors ambient sound levels.
This is increasingly essential as cough frequency has become an efficacy endpoint in FDA-reviewed chronic cough programs and regulatory expectations continue to sharpen around measurement validity, traceability, and interpretability.
Hyfe is built to deliver regulator-grade objective cough endpoints and trend insights (cough bouts, cough-free time, cough variability, among other) without adding burden for patients, sites, or study teams.
Hyfe turns cough into a continuous, quantitative endpoint, capturing real-world variability and enabling more sensitive detection of treatment effects than episodic assessments or self-report.

High-quality data without trade-offs. On-device processing avoids audio capture (no one listens to participant conversations) and reduces privacy risk, while passive monitoring supports strong adherence.

Built for where regulation is heading. Objective cough frequency is already being used as an efficacy endpoint in FDA-reviewed programs, and the expectations are clear: validated methods, traceability, and clinical interpretability. Hyfe is designed to meet these expectations.

DTx proof-of-concept results presented at CHEST 2025 in Chicago: 41.8% reduction in cough frequency and 80% of participants reporting clinically meaningful improvement in quality of life.
Multiple abstracts presented at ATS 2025 covering optimal monitoring duration, cough bout metrics, and the DTx proof-of-concept.
Six-month TB treatment monitoring study from Madagascar published in ERJ Open Research, showing cough rates dropping from 11.0 to 3.5 coughs/hour during treatment.
Scoping review in The Lancet Digital Health independently validates Hyfe as one of the leading non-contact autonomous cough detection systems.
Announces strategic partnership with KYORIN Pharmaceutical to develop and commercialize the world's first prescription digital therapeutic for chronic cough in Japan, with milestone payments and royalties.
Formal product launch of the ActiGraph-Hyfe combined digital health solution on ActiGraph's LEAP wearable platform.
Publishes multicenter clinical validation in Nature Scientific Reports showing 90.4% sensitivity, 1.03 false positives per hour, and 0.99 Pearson correlation with manual counts across 546 hours and 4,454 cough events.
733,756-cough TB dataset from 2,143 patients across 7 countries published in Nature Scientific Data.
Collaboration with Sensory Cloud Inc. published in ERJ Open Research showing an inhaled alkaline salt aerosol reduced cough frequency by up to 35% in refractory chronic cough patients, monitored using the Hyfe CoughMonitor Suite.
COVID-19 prognostication study published in Journal of Biomedical Informatics showing higher early cough rates predicted more favorable outcomes
Tamsin Chislett transitions into the CEO role, reflecting the company's shift from founder-led R&D to commercial scaling.
Landmark validation study published in BMJ Open Respiratory Research showing Hyfe's AI is nearly as accurate as the human ear in detecting coughs, including the first-ever observation of sex differences in cough characteristics.
Partners with ActiGraph to integrate cough detection into ActiGraph's FDA-cleared LEAP wearable for clinical research.
Dr. George Savage (co-founder of Proteus Digital Health) and Dr. Laurie Slovarp (world's leading BCST clinician) join the Scientific Advisory Board.
Announces plans to launch the world's first digital therapeutic (DTx) for chronic cough, incorporating Behavioral Cough Suppression Therapy (BCST).
Named to the CB Insights Digital Health 150 list, selected from 13,000 private companies as one of the most promising digital health companies globally.
Multiple publications in ERJ Open Research and Lung demonstrate continuous longitudinal cough monitoring reveals patterns invisible to short-term assessments.
Presents at the European Respiratory Society (ERS) Congress in Barcelona.
Announces partnership with Merck to integrate Hyfe's AI cough tracker into Merck's consumer disease education efforts targeting an estimated 12 million U.S. adults with chronic cough.
Presents at the ATS 2022 Respiratory Innovation Summit with poster "Hyfe Cough Monitoring System: Making Cough Count."
Dr. Peter Small addresses the G20 meeting in Yogyakarta, Indonesia on digital innovation in combating tuberculosis.
Featured in the Wall Street Journal ("Coughs Say a Lot About Your Health, If Your Smartphone Is Listening").
Hyfe's app incorporated into a year-long respiratory research trial with the University of Navarra, Zizur's Health Center, and Montreal University Hospital Center.
Dr. Peter Small appointed Chief Medical Officer, bringing credentials from Stanford Medical School, the Bill & Melinda Gates Foundation (where he developed the TB strategy), and as Founding Director of the Global Health Institute at Stony Brook University.
First major protocol paper published in BMJ Open, describing the digital acoustic surveillance study design deployed in Pamplona, Spain.
Partners with ObvioHealth to integrate cough tracking into their decentralized clinical trials platform — Hyfe's first clinical trials partnership.
Joins the Creative Destruction Lab and Health Engine Accelerator programs.
Closes ~$1M seed round led by a private investor with participation from Plug and Play Ventures.
Hyfe joins the Plug and Play accelerator program.
Core AI technology development begins: a machine-learning engine that detects, classifies, and counts coughs from ambient sound on any device with a microphone, processing entirely on-device to preserve privacy.
Reid Moorsmith joins as Director of Consumer Products, bringing global health operations experience from PSI programs in Liberia and Myanmar.
Hyfe founded by Joe Brew (epidemiologist/data scientist), Iulian Circo (serial entrepreneur), and Paul Rieger (software developer) in Wilmington, Delaware.